Clinical Trial Update: Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating romiplostim for increasing low platelet counts in multiple myeloma patients receiving chemotherapy; study terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: NYU Langone Health | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2017-09-05